Serum HER2 extracellular domain (ECD) levels and efficacy of weekly (W) or every 3-weekly (q3W) paclitaxel (P) with or without trastuzumab (T) in patients (pts) with metastatic breast cancer (MBC): CALGB 150002/9840 Meeting Abstract

  

Authors:	Seidman, A. D.; Broadwater, G.; Carney, W.; Dressler, L.; Berry, D.; Norton, L.; Hudis, C.; Winer, E.; Ellis, M.; Harris, L.
Abstract Title:	Serum HER2 extracellular domain (ECD) levels and efficacy of weekly (W) or every 3-weekly (q3W) paclitaxel (P) with or without trastuzumab (T) in patients (pts) with metastatic breast cancer (MBC): CALGB 150002/9840
Meeting Title:	41st Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	23
Issue:	16 Suppl.
Meeting Dates:	2005 May 13-17
Meeting Location:	Orlando, FL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2005-06-01
Start Page:	18S
Language:	English
ACCESSION:	WOS:000230326600071
PROVIDER:	wos
DOI:	10.1200/jco.2005.23.16_suppl.558
Notes:	--- - Meeting Abstract: 558 - 41st Annual Meeting of the American-Society-of-Clinical-Oncology - MAY 13-17, 2005 - Orlando, FL - S - Part 1 - "Source: Wos"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/44903